Scarica l'app Stockscreener
131.63
0.74%
0.97
Precedente Chiudi:
$130.66
Aprire:
$131.72
Volume 24 ore:
870.15K
Relative Volume:
0.61
Capitalizzazione di mercato:
$10.63B
Reddito:
$8.19B
Utile/perdita netta:
$758.19M
Rapporto P/E:
14.34
EPS:
9.18
Flusso di cassa netto:
$1.06B
1 W Prestazione:
-1.74%
1M Prestazione:
-8.30%
6M Prestazione:
-30.59%
1 anno Prestazione:
-58.32%
Intervallo 1D:
$129.25
$133.62
Intervallo di 1 settimana:
$129.25
$142.58
Portata 52W:
$129.25
$347.72
Icon Plc Stock (ICLR) Company Profile
Nome
Icon Plc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ICLR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
131.63 | 10.65B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
412.06 | 152.18B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.11 | 135.78B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
518.10 | 39.54B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.77 | 30.49B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
142.82 | 25.78B | 15.50B | 1.33B | 2.16B | 7.34 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Downgrade | TD Cowen | Buy → Hold |
| 2025-04-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Iniziato | Redburn Atlantic | Neutral |
| 2024-09-18 | Iniziato | Leerink Partners | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2023-12-15 | Iniziato | Truist | Buy |
| 2023-09-13 | Iniziato | TD Cowen | Outperform |
| 2023-01-17 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-09-07 | Iniziato | UBS | Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-05-24 | Iniziato | Guggenheim | Buy |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-14 | Iniziato | Citigroup | Neutral |
| 2021-04-13 | Ripresa | BofA Securities | Neutral |
| 2021-04-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Iniziato | Barclays | Equal Weight |
| 2021-03-01 | Aggiornamento | UBS | Neutral → Buy |
| 2021-02-26 | Aggiornamento | Truist | Hold → Buy |
| 2020-07-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Hold |
| 2020-01-27 | Downgrade | SunTrust | Buy → Hold |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-09-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Aggiornamento | UBS | Sell → Neutral |
| 2019-01-25 | Aggiornamento | Mizuho | Neutral → Buy |
| 2018-10-26 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Iniziato | UBS | Sell |
| 2018-04-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Reiterato | Mizuho | Neutral |
| 2018-01-19 | Iniziato | Evercore ISI | Outperform |
| 2017-10-27 | Reiterato | Barclays | Equal Weight |
| 2017-09-11 | Iniziato | BofA/Merrill | Buy |
| 2017-07-31 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-27 | Reiterato | Mizuho | Neutral |
| 2017-06-29 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Icon Plc Borsa (ICLR) Ultime notizie
Icon (ICLR) Price Target Reduced by Mizuho to $173 | ICLR Stock News - GuruFocus
ICON Life Science Internship For BSc & MSc – Applications Closing Soon! Hurry! - BioTecNika
Daily Progress: Icon Plc (ICLR) Drop -5.54, Closing at 135.10 - DWinneX
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies | ICLR Stock News - GuruFocus
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies - Business Wire
Icon (ICLR) Stock Target Reduced Amid Market Challenges | ICLR S - GuruFocus
Icon (ICLR) Stock Target Reduced Amid Market Challenges | ICLR Stock News - GuruFocus
ICON plc (ICLR) Consensus: A 29% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Icon Plc Earnings Call: Navigating Challenges and Opportunities - TipRanks
Icon (ICLR) Sees Price Target Adjustment by Barclays | ICLR Stock News - GuruFocus
ICON plc Expands Share Buyback Program Amid Vaccine Study Delays and Tariff Uncertainty - TipRanks
Icon Plc [ICLR] Officer makes an insider purchase of 1,540 shares worth 0.29 million. - knoxdaily.com
Market Analysts see Icon Plc [ICLR] gaining to $150. Time to buy? - dbtnews.com
Icon (ICLR) Price Target Reduced by BofA Analyst | ICLR Stock Ne - GuruFocus
ICLR Faces Revenue Pressure Amid Elevated Cancellations - GuruFocus
Barclays Adjusts Price Target for Icon (ICLR) Amid Uncertain Out - GuruFocus
Barclays Adjusts Price Target for Icon (ICLR) Amid Uncertain Outlook | ICLR Stock News - GuruFocus
Icon PLC (ICLR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives - Yahoo Finance
ICON plc Reports Q1 2025 Financial Results - TipRanks
Icon Earnings: Macroeconomic Issues and Trial Delays Affect Our Near-Term View - Morningstar
Narrow-Moat Icon Faces Macroeconomic Issues and Trial Delays That Constrain Its Near-Term Outlook - Morningstar
The Future of Icon Plc: Analyzing ICLR - investchronicle.com
A look at ICLR’s current quarter earnings estimates - uspostnews.com
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down - Yahoo Finance
Icon PLC: Q1 Earnings Snapshot - MySA
ICON PLC earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Icon PLC (ICLR) Beats Q1 Earnings Estimates - Yahoo Finance
ICON PLC reports results for the quarter ended March 31Earnings Summary - TradingView
ICON PLC earnings beat, revenue fell short of estimates - Investing.com
ICON plc Reports Q1 2025 Financial Results Amid Market Challenges - TipRanks
ICON Reports First Quarter 2025 Results | ICLR Stock News - GuruFocus
Earnings Flash (ICLR) ICON PLC Reports Q1 Adjusted EPS $3.19, vs. FactSet Est of $3.10 - marketscreener.com
Earnings Flash (ICLR) ICON PLC Posts Q1 Revenue $2B, vs. FactSet Est of $2.01B - marketscreener.com
ICON Reports First Quarter 2025 Results - Business Wire
Icon Plc (NASDAQ: ICLR) Shares Are Down -29.22% Year To Date. - Marketing Sentinel
Checking in on Icon Plc (ICLR) after recent insiders movement - knoxdaily.com
Icon (ICLR) Downgraded by JPMorgan Amid Uncertain Market Conditi - GuruFocus
Icon (ICLR) Downgraded by JPMorgan Amid Uncertain Market Conditions | ICLR Stock News - GuruFocus
ICON plc (ICLR) Stock Analysis: Uncovering a 44.70% Potential Upside in Healthcare Research - DirectorsTalk Interviews
ICLR Stock Sees Surge of Approximately 1.66% in Last Five Days - knoxdaily.com
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for - MSN
Icon PLC (ICLR) Stock Price Up 4.72% on Apr 23 - GuruFocus
Recent Insider Activity Could Benefit Icon Plc (ICLR) - knoxdaily.com
Icon Plc (ICLR)’s Day in Review: Closing at 137.23, Down by -1.50 - DWinneX
ICON plc (ICLR): A Deep Value Play with 53% Upside Potential - DirectorsTalk Interviews
ICON Plc stock hits 52-week low at $138.47 amid market challenges - Investing.com Canada
ICON Plc stock hits 52-week low at $138.47 amid market challenges By Investing.com - Investing.com South Africa
Clinical Trial Investigative Site Network Market Top Companies - openPR.com
Clinical trials giant Icon accused of ‘scheme to deceive market’ in new US class action - The Irish Independent
TD Cowen Downgrades Icon (ICLR) Amid Concerns Over Future Growth - GuruFocus
ICON plc (ICLR) Stock: A 54.73% Potential Upside That Investors Can’t Ignore - DirectorsTalk Interviews
Icon Plc Azioni (ICLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):